𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder

✍ Scribed by Farhad Soltani; Mehdi Sayyah; Fariba Feizy; Alireza Malayeri; Amir Siahpoosh; Ismail Motlagh

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
82 KB
Volume
25
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive‐compulsive disorder (OCD).

Methods

The study was an 8‐week pilot double‐blind randomized clinical trial. Forty‐two adult outpatients who met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM‐IV‐TR) criteria for OCD based on the structured clinical interview participated in the trial. In this study, patients were randomly assigned to receive either ondansetron (4 mg) plus fluoxetine or fluoxetine (20 mg/day) plus placebo.

Results

The results showed a significant difference between two groups in the treatment of OCD (based on t‐test). There was not any significant difference between the two groups in terms of observed side effects.

Conclusions

The results of this study show that ondansetron has positive effects on obsession and compulsion which start two weeks after the beginning of the treatment. Copyright Β© 2010 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

Treatment of postinfectious olfactory di
Treatment of postinfectious olfactory disorders with minocycline: A double-blind, placebo-controlled study
✍ Jens Reden; Birgit Herting; Katja Lill; Robert Kern; Thomas Hummel πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 134 KB

Objectives/Hypothesis: Infection of the upper respiratory tract is one of the most common causes of olfactory loss. One of the possible underlying pathologic pathways is an increase of apoptosis of olfactory receptor neurons. Therefore, treatment with the antibiotic minocycline, which has been shown

Rifaximin for the treatment of active po
Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study
✍ Kim L. Isaacs; Robert S. Sandler; Maria Abreu; Michael F. Picco; Stephen B. Hana πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 132 KB πŸ‘ 2 views

## Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. ## Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. eighteen patients with

A double-blind, placebo-controlled study
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
✍ Nancy J. Olsen; Raye H. Brooks; John J. Cush; Peter E. Lipsky; E. William St. Cl πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 654 KB

Objective. To evaluate the efficacy of an antLCD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CDS-IC. Results. Treatment with CD

A 24-week, double-blind, placebo-control
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's diseaseβ€”pilot study
✍ Vee. P. Prasher; Adam Huxley; M. S. Haque πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 163 KB πŸ‘ 1 views

## Abstract ## Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. ## Method This